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A b s tr a c t -A n l io x id a n ts  such as vitamin B protect unsaturated fatty acids of L D L  against oxidation. In the cx vivo model used, 
LDL was exposed to Q r M ions, a potent prooxidanl capable of initiating the oxidation o f  LD L. The lag time, indicating the 
delay o f  conjugated dienc formation in LD L due to antioxidant protection, was measured in 54  cystic fibrosis ( C F )  patients 
with plasma ^-tocopherol levels below (Group A, n ~  30) or above (Group B, n =  2 4 )  15.9 ¿¿mol/L (mean ~~ 2 SD  o f  *Swiss 
population). Patients were reevaluated after 2 months on 400  lU /d  of oral RRR-a-tocophcrol. In group A, «-tocopherol 
concentrations in LD L increased significantly from 3.2 ±  1.6 mol/mol LD L to 8 .2  ±  2.8 mol/niol (P  <  0 .0 0 1 )  and lag times 
increased from 79 ±  33 min to 126 ±  48 min {P  <  0 ,0 0 1 ) ,  whereas in the vitamin E sufficient group B no further increase 
neither in LD L «-tocopherol concentrations or in lag times was observed, L D L  oleic acid concentrations were higher, and 
linoleic acid concentrations were lower in patients than in controls. After efficient vitamin E supplementation, lag times were 
positively related to LDL ar-tocopherol (P  <  0 .01) and negatively to L D L  linoleic and arachidonie acid content (P  <  0 ,0 0 1 ) .  
The maximum rate o f  oxidation correlated positively with linoleic and arachidonic acid concentrations, as did the maximum 
conjugated dicne absorbance. These results indicate that LD L resistance to oxidation is impaired in vitamin E  deficient C F  
patients but can be normalized within 2 months when a-tocophcrol is given in suflicicnL amounts. Linoleic and arachidonic acid 
content exhibit a major influence on the LDL resistance to oxidation.
Keywords ^-Tocopherol, Low density lipoprotein, Oxidation resistance, Linoleic acid, Arachidonic acid, Cystic fibrosis, Free 
radicals
IN T R O D U C T IO N
As a consequence of fat malabsorption due to cxocrine 
pancreatic insufficiency, 1 subclinical vitamin E defi­
ciency is a frequent finding in patients with cystic fi­
brosis (C F ) .  In contrast, symptomatic vitamin E  defi­
ciency is a rare event.2 To prevent and treat vitamin E  
deficiency, oral vitamin E  supplementation has become 
part of the therapeutic management of CF patients. 
However, vitamin E  deficiency is not always reversed 
by routine vitamin E  supplementation.1,4
Thus far, data on the biological significance of sub-
Address correspondence to: Brigitte M. Winklhofer-Roob, Depart­
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clinical vitamin E  deficiency in C F patients are limited. 
Chronic lung inflammation is suggested to cause an 
increased release of oxygen-derived free radicals in the 
presence of antioxidant deficiencies due to fat malab­
sorption, and the resulting oxidant—antioxidant imbal­
ance could lead to an enhanced free radical attack of 
polyunsaturated fatty acids (P U F A s) of biomembranes 
and lipoproteins and, consequently, to tissue injury,5 
Data on the occurrence of lipid peroxidation in CF  
patients is available from determinations of in vitro 
peroxide induced red cell hem olysis/’ thiobarbiiuric 
acid reactive substances, 7 and hydrocarbon gas exhala-
tion. R,‘>
The aim of this study was to determine the signifi­
cance of subclinical vitamin E  deficiency on the LD L  
resistance to in vitro oxidative stress and the effects
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of correcting this deficiency in CF patients. In addition, 
relationships between the LDL resistance to oxidation 
and the fatty acid content of LDL were analyzed.
SUBJECTS
Patients
Fifty-four CF patients under long-term care in the 
CF outpatient clinics of 10 different hospitals in Swit­
zerland, Austria, and Germany were enrolled. Their 
ages ranged from 3 months to 34 years (median 9 
years). The diagnosis of CF had been established by 
typical clinical symptoms and elevated sweat electro­
lytes.10 All patients exhibited exocrine pancreatic in­
sufficiency and were treated with pancreatic enzymes. 
Twenty-four patients were on long-term oral vitamin 
E supplementation in dosages of 50 to 800 lU/d prior 
to study entry. Shwachman scores, 11 indicating the 
clinical disease status, were 77 ±  19. No changes were 
introduced in the therapeutic management during the 
study period, except for intermittent antibiotic treat­
ment of acute pulmonary exacerbations. Patients were 
considered vitamin E deficient and assigned to group A 
if they had plasma a-tocopherol concentrations below 
mean -  2 SD of the Swiss population (15.9 ¿¿mol/1)12; 
accordingly, those with plasma a-tocopherol concen­
trations >  15.9 /¿mol/1 were assigned to group B.
Immediately after the baseline evaluation, patients 
without supplements (n =  30) or with dosages <  400 
IUId  (n =  12) were switched to 400 IU/d of RRR- 
a-tocopherol, given in a single dose during breakfast. 
Patients who were already taking vitamin E supple­
ments in dosages of 400 IU/d ( n =  9 ), 600 IU/d 
( n =  1), and 800 IU/d (n =  2) continued to do so.
Forty-seven of 54 patients had a second evaluation 
after 2 months on vitamin E. Drop-outs were due to 
death (n  =  2 ), movement to another country (n =  2 ), 
or vacation (n =  3 ). In two patients, either LDL a - 
tocopherol concentrations at baseline or lag time values 
at 2 months were missing. Thus, a complete set of data 
for statistical analysis was available from 53 patients 
at baseline and 46 patients at 2 months.
Controls
Twenty-three clinically healthy normolipidemic 
nonsmoking staff members aged 26 ±  7 years from 
the Departments of Pediatrics, University of Zurich 
(n  =  21), and University of Innsbruck (n =  2 ) served 
as controls because it was ethically not acceptable to 
draw the necessary amounts of blood from healthy 
children. None of the controls was taking vitamin sup­
plements or medications other than oral contraceptives
(n  -  6 ). All were on a regular diet. Controls had 
a single evaluation including the same parameters as 
assessed in patients to allow, by comparison, validation 
of baseline values and evaluation of treatment efficacy.
The study protocol was approved by the Ethical 
Committee of the Department of Pediatrics, University 
of Zurich, and informed consent was obtained from 
the patients or their parents and from controls.
METHODS
Immediately after blood was drawn after an over­
night fast, EDTA (0.1%  final) plasma was prepared 
and protected from light with aluminum foil by the 
same investigator (B.M .W .R.) in all CF centers.
Determination o f  LD L antioxidants and LD L  
resistance to oxidation
The freshly prepared plasma samples (3 to 4 ml) 
were shipped on wet ice by overnight courier to the 
Institute of Biochemistry, University of Graz. LD L  
was isolated by ultracentrifugation in a discontinuous 
potassium bromide gradient containing 0.1% EDTA  
using a Beckman SW 41 Ti-rotor, as described pre­
viously.13 The LDL band was quantitatively collected 
and diluted with PBS to give the same volume as the 
centrifuged plasma sample (3 to 4 ml). The total cho­
lesterol concentrations of the LD L stock solutions were 
determined with the CHOD-PAP kit from Boehringer 
Mannheim. Based on this analysis, the LDL concentra­
tion was calculated as mg LD L mass/ml and /umol 
LDL/1, respectively, assuming an LD L cholesterol 
content of 31.6 wt % and a molecular weight of 2500  
kD both for CF patients and healthy subjects. An ali­
quot of the LDL stock solution was stored at 4°C for 
not longer than 6 h for the determination of antioxi­
dants. Another aliquot was used immediately for the 
oxidation assay. For the latter, EDTA and salt were 
removed nsing prepacked Biogel P6 columns. Oxida­
tion was then performed under standardized condi­
tions13 with 0.1 ¡jM  LD L in PBS (equal to 0.25 ml 
LDL mass/ml) and L 66 jjM  CuCl2. The oxidation of 
LDL was monitored spectrophotometrically by mea­
suring the conjugated diene (C D ) absorbance at 234  
nm. The oxidation indexes derived from the CD versus 
time curves are lag time, maximum rate of oxidation 
(dA/min), and maximum increase in CD absorbance 
(A234). This oxidation assay has proved to be repro­
ducible with CV for multiple analyses of the same 
LDL sample of 1 .85% 13 and multiple analyses of LDL  
from a single donor of 8 .8% .14
Antioxidants in LDL were determined as described
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Table 1. Tocopherol and Carotenoid Concentrations in Plasma and in LDL at Baseline and After 2 Months of Vitamin E Supplementation 
in Group A (Plasma a-Tocopherol <  15.9 ¿¿mol/1) and Group B (Plasma a:-Tocopherol >  15.9 ¿¿mol/1) as Well as in Controls
Patients Baseline 2 Months
Group A Group B Group Group A
Baseline 
vs. 2 Group B
Baseline 
vs. 2 Control sb
{n =  30) (« :- 2 4 ) A vs. B a Cn -  27) Monthsb (n =  20) Months'1 (n =  23)
Plasma (//mol/1)
or-tocopherol 9.0 ±  4.2C 28.3 ±  9.3 <  0.0001 27.8 ±  8.1 <  0.0001 35.3 ±  9.0d <  0.05 26,9 ±  5.1wl
y-tocopherol 0.76 ±  0.60 0.48 ±  0.43 NS 0.34 ±  0.33 <  0.001 0.25 ±  0.17 <  0.01 1.59 ±  0.61
a-carotene 0.02 ±  0.05 0,06 ±  1.11 <  0.05 0.03 ±  0.07 <  0.05 0.05 ± 0 . 1 0 NS 0.18 ±  0.08
^-carotene 0.09 ±  0.11 0.22 ±  0.33 <  0.05 0.10 ±  0.15 NS 0.21 ±  0.40 NS 0.80 ±  0.37
Lycopene 0.03 ±  0.03 0.06 +  0.06 <  0.05 0.05 ±  0.05 <  0.001 0.09 ±  0.07 <  0.01 0.54 ±  0.28
LDL (mol/mol)
a-tocopherol 3.2 ±  1.6 8.5 ±  3.1d <  0.0001 8.2 ±  2.& <  0.0001 9.4 ±  3,5J NS 5,0 ±  0.8d
y-tocopherol 0.27 ±  0.19 0.16 ±  0.15 <  0.01 0.12 ±  0.13 <  0.001 0.05 ±  0.06 <  0.001 0.32 ± 0 . 1 4
a-carotene 0.003 ±  0.005 0.02 ±  0.03 NS 0.008 ±  0.02 NS 0.02 ±  0.04 NS 0.04 ±  0.02
/2-carotene 0.04 ±  0.06 0.09 ± 0 . 1 8 <  0.05 0.04 ±  0.04 NS 0.12 ±  0.25 NS 0.25 ±  0.12
Lycopene 0.02 ±  0.04 0.04 ±  0.05 <  0.05 0.04 ±  0.03 <  0.05 0.05 ±  0.05 NS 0,31 ±  0,15
Lutein/Zeaxanthine 0.02 ±  0.01 0.03 ±  0.02 <  0.01 0.02 ±  0.01 NS 0.03 ±  0,02 NS 0.09 ±  0.06
Cryptoxanthine 0.009 ±  1.01 0.009 ±  0.01 NS 0.01 ±  0,01 NS 0.01 ±  0.02 <  0.05 0.10 ±  0.06
Values are mean ±  SD. Identical superscripts indicate significant differences for a-tocopherol between patients and controls. 
a Mann-Whitney tests, two tailed. 
b Wilcoxon signed ranks test.
CP <  0.0001. 
dP <  0.001.
previously.15,16 In brief, a sample of the LDL stock 
solution containing 0.5 mg LDL mass was mixed with 
0.2 ml methanol and extracted with 1 ml hexane, and 
the extract was dried with nitrogen and taken up in 0.1 
ml HPLC solvent, a - and y-Tocopherol were deter­
mined by HPLC (O D S-2), using methanol as solvent 
and fluorimetric detection at 335 nm with 292 nm exci­
tation. Carotenoids were separated on an ODS-2 col­
umn with acetonitrile/dichloromethane/methanol 67/ 
19/4  and UV/VIS detection at 436 nm. Calibration 
»
was based on standards separated under identical con­
ditions after every 10 samples.
Determination o f fatty acids in LDL
The freshly prepared EDTA plasma samples (2.5  
to 3.0 ml) were immediately frozen at — 80°C and kept 
at this temperature for not longer than 2 months until 
analysis. LDL was prepared from the freshly thawn 
samples by 2 h ultracentrifugation using a single-step 
discontinuous gradient in a Beckman NVT65 rotor17 
(note that this rotor, which allows isolation of LDL  
within 2 h, was not yet available at the time when LD L  
oxidation experiments were performed). The plasma 
volume after centrifugation was in the range of 2.5 to
Table 2. Parameters of LDL Resistance to Oxidation at Baseline and After 2 Months of Vitamin E Supplementation in
Group A and Group B as Well as in Controls
-------- - . ------------- .. ----------------------- -- -------------------------------- ----------- --------------- ----------------------  "  i—^ ^ ^
Patients Baseline 2 Months r
Group A 
(n =  30)
Group B 
(n =  24)
Group 
A vs. B“
Group A 
(n -  27)
Baseline 
vs. 2 
Monthsh
Group B 
(H =  19)
Baseline 
vs. 2 
Monthsb
Controls 
(n =  23)
Lag time (min) 79 ±  33e li t ±  30 <  0.001 126 ±  48e <  0.001 127 ±  29J NS 99 ±  29'"‘l
Oxidation rate
dA/min 0.011 ±  .003 0.011 ±  0.003 NS 0.010 ±  0.004 NS 0.011 ±  1.004 NS 0.012 ±  0.006
Time (min) 119 ±  40 151 ±  40 <  0.01 173 ±  61 <  0.001 169 ±  35 NS 141 ±  39
CD absorbance
A 234 nm 0.66 ±  0,14 0.69 ±  0.23 NS 0.69 ±  0.14 NS 0.77 ±  0.13 <  0.05 0.70 ±  0.17
Time (min) 188 ±  55 212 ±  52 NS 236 ±  71 <  0 .0 1 245 ±  69 NS 200 ±  48
Values are mean ±  SD.
0 Mann-Whitney tests, two tailed. 
b Wilcoxon signed ranks tests.
Identical superscripts indicate significant differences between patients and controls: c p  <  0.05, p <  0.01.
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Baseline LDL <x-tocopherol (mol/mol)
Fig. 1. Lag times of 53 CF patients are plotted against baseline LDL 
a-tocopherol concentrations. One patient is not included due to LDL 
a~tocopherol value missing.
were determined in plasma by HPLC according to Hess 
et al.19
STATISTICAL ANALYSIS
Due to nonconformity of the data with the normality 
assumption, nonparametric tests were used for compar­
isons of antioxidant concentrations and the LDL resis­
tance to oxidation at baseline and after 2 months of 
vitamin E supplementation. For within-group compari­
sons, Wilcoxon signed ranks tests were applied; for 
comparisons between groups, Mann-Whitney tests 
were used. Statgraphics (STSC Inc., Rockville, MD) 
Version 6 was used for all statistical procedures. Dif­
ferences were considered significant at P  <  0.05. All 
results are expressed as mean ±  SD.
3 ml. The LDL band was quantitatively collected and 
diluted with PBS to obtain exactly the same volume, 
as was the plasma volume originally present in the 
centrifuge tube. Cholesterol concentrations were deter­
mined as described earlier, and LDL cholesterol con­
centrations were calculated as mg LDL mass/ml and 
as /imol LDL/1, respectively. A sample of the LDL 
solution containing 1 mg LDL mass was spiked with 
100 /ig heptadecanoic acid and freeze dried in 10-ml 
Pyrex tubes. BHT (0.5 mg), BF^/methanol (1 ml), 
and benzene (0.5 ml) were added to the dry residues, 
and the samples were subjected to transesterification 
at 110°C for 90 min. The fatty acid methyl esters were 
extracted into hexane and separated by GC. The GC 
separation was performed with a HP5890 Series II 
instrument. More details of the whole procedure can 
be found in ref. 18.
Determination o f plasma total cholesterol and LD L  
cholesterol concentrations
Plasma total cholesterol concentrations were mea­
sured enzymatically, using a commercially available 
kit from Beckman Ltd. (Brea, C A ). Plasma LDL cho­
lesterol concentrations were determined with a kit from 
BioMerieux Suisse SA (Geneva, Switzerland).
Determination o f  plasma antioxidants
Another aliquot of EDTA plasma was stored at 
—20°C for a maximum of 3 days before shipment on 
dry ice to the laboratories of the Vitamin Research 
Department of Hoffmann-La Roche Ltd. (Basel, Swit­
zerland), where a -  and 7 -tocopherol and carotenoids
RESULTS
Applying the cutoff value for plasma a-tocopherol 
concentrations of 15.9 fj,mol/1, 12 30 patients were con­
sidered vitamin E  deficient (group A ), whereas 24 
patients had a sufficient vitamin E  status, in most cases 
due to long-term vitamin E  supplementation prior to 
study entry (group B ) .  Six patients of group A had 
been on supplements (median dosage, 100 IU /d) and 
18 patients of group B (300  IU /d ). Accordingly, base­
line plasma and LDL a-tocopherol concentrations were 
significantly lower in group A compared with group 
B and with healthy controls (Table 1). Plasma a-to­
copherol concentrations correlated positively with 
LDL a-tocopherol concentrations ( r  =  0.85, P — 
0.0001). There were no differences between groups A
150
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Fig. 2. Changes in lag times during vitamin E  supplementation are 
plotted against changes in LDL a-tocopherol concentrations in 45 
patients. One patient who completed the study is not included due 
to LDL a~tocopherol value missing at baseline.
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Table 3. Fatty Acids in LDL at Baseline and After 2 Months of Vitamin E Supplementation in Group A and Group B
Group A Group B
Baseline 
(n 30)
2 Monlhs
(// ~ 24)
Baseline 
(m -  24)
2 Months
( n  =  20) pu
Patients 
(n =  54)
Controls 
in  =  23)
DB 33 IK.2 41V» é ‘>06,7 3352.0 881.8 NS 3532.0 714.5 3380.4 ■i" 402,1 NS 3415.0 ± 824.6 3251.2 452,4 NS
C l 6:0 744.0 2)8.8 687.4 142.6 NS 731.9 190.6 637.1 ± 99.5 <  0.05 738.5 204.7 533.6 ± 90.3 < 0.0001
('16:111-7 130.1 ■1*•W H i 68.8 113.2 hI* v » 57.7 NS 106.6 46.5 87.7 39.4 NS 119.5 ± 60.4 50.8 i t 18.8 < 0.0001
C l 8:0 201.1 1 57.3 195.1 47.0 NS 203.8 47.4 182.5 ± 20.2 NS 202.3 ± 52.5 151.0 20.5 < 0.0001
C l 8: ln-9 722.8 * M» 224.1 696.1 f> J a• t ,  4 137.1 NS 745.8 193.6 662.7 ± 119.8 NS 733.2 ± 209.2 458.5 ■4- 91.7 < 0.0001
C^B:)M“7 60,6 28.2 54. ) i |- 0 . 4 19.4 NS 82.1 ‘1- J50.5 44.3 •**- 13.0 NS 56.8 ± 24.6 31.1 6.3 < 0.0001
CI8:2n-6 7l) 1.6 •-I; 32.98 820.8 a} . 306,3 NS 858.4 r> 240.5 890.0 165.4 NS 821.8 -f-UM# 291,5 949.0 ± 98.8 < 0.01
C l 8::in-3 12.8 •► 4.4 12.8 • > é 6.0 NS 13.5 •I" 5.8 12.4 6.7 NS 13.1 -Jr 5.0 13.5 ± 4.5 NS
C20:4n 6 145.5 *• 51.4 160.5 -  O 57.1 <  0.05 151.0 V 48.3 147.9 -1- lé +  i 35,2 NS 148.0 H* 49,6 134.2 ± 38.0 NS
C22;6n-3 33.4 12.8' 30.9 4'1  . 4 12.6 <  0.05 39.3 11.0° 29.5 ± 10.7 <  0.05 36.1 12.3 645.7 4* (4.8 < 0.0!
As there were no differences between groups A and B cxcept for C22:6n-3 {P <  0.05), groups A and B baseline were combined for 
comparison with controls. DB «  Double bonds. Units are inol/mol; values are Mean £  SD,
11 Wilcoxon signed ranks tests.
11 Mann-Wbitney tests, two tailed.
Identical superscripts indicate u significant difference between group A and B: CP <  0.05.
and B with regard to age (11 ,8  ±  8.3 years vs. 9.9 ±  
8.2 years) and Shwaehman scores (75 .2  ±  17.9 years 
vs. 79 .6  ±  19.2 years).
Oral vitamin E supplementation in a dosage of 400  
IlJ/d was well tolerated in all patients, and none experi­
enced any side effects, as detected by clinical examina­
tion and standard laboratory techniques. After 2 months 
of vitamin E supplementation, plasma a-locophcrol con­
centrations had significantly increased in both groups, 
whereas LD L «-tocopherol levels increased only in the 
vitamin E deficient group A. Plasma and LDL a-tocoph- 
erol concentrations were higher in the vitamin E suffi­
cient group B than in controls (Table 1).
The LD L cholesterol content of plasma was sig­
nificantly lower in patients (1 .56  ±  0.38 mmol/1) 
compared with controls (2 .9 4  ±  0.59 mmol/1) 
( P <  0 .0 0 0 1). It did not differ between group A ( 1 ,56  
±  0 .38 mmol/1) and group B (1 .80  ±  0 ,54 mmol/1) 
at baseline and did not change during the study period 
(2  months: group A, 1.53 ±  0.46 mmol/1; group B,
1.75 ±  0 .62 mmol / 1). The same was found for plasma 
total cholesterol concentrations (at baseline, group A,
2.85 ±  0.59 mmol/1; group B, 3 ,17  ±  0 .77  mmol/1, 
compared with controls, 4 .8 3  ±  0,68  m m ol/1).
Both in plasma and in L D L , 7 -tocopherol and carot- 
enoid concentrations were significantly lower in pa­
tients than in controls (Table 1 ) ,  /3-carotene concentra­
tions were higher in group B compared with group A; 
they did not change during the study period, In con­
trast, 7 -tocopherol concentrations decreased in both 
groups, and some of the carotenoids increased either 
in plasma or in L D L  or in both, but still remained 
lower than in controls (Table 1 ) .
At baseline, lag times were significantly shorter in 
group A compared with group B ( P  =* 0,001 ) and with 
controls ( P  =  0 .0 3 )  (Table 2 ) .  Lag  times correlated 
positively with LD L «-tocopherol concentrations (Fig.
1 ) . After 2 months of vitamin E  supplementation, a 
significant increase in lag times was observed only in 
group A (P  ~  0 .0001 ) .  Changes in lag time correlated 
with changes in L D L  a-tocopherol concentrations 
(Fig. 2 ) .  After supplementation, lag times of group A 
and group B were similar and even significantly longer 
than those o f controls (Table 2 ) .
Table 4. Results of Regression Analyses for Indexes of the LDL Oxidizability
and LDL a-Tocopherol and Fatty Acid Content
«-Tocopherol C18:2n-6 C20:4n-6
Baseline
Lag time P =  0.0001 NS NS
Oxidation rate NS P =  0.0003 NS
Maximum CD absorbance NS P «  0.00001 P «  0.006
2 Months
Lag time P =  0.002 P «  0.0002 P =  0.0006
Oxidation rate NS P *= 0.0003 P «  0 . 0 0 0 1
Maximum CD absorbance P *  0.00005 P «  0,00001 P =  0.0001
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Fig. 3. The maximum CD absorbancc after 2 months of vitamin H 
supplementation is plotted against the LDL a-toeophero! conlenl for 
46 patients who completed the study,
At baseline, no differences were observed in the 
maximum rate of oxidation and the maximum CD ab­
sorbance, neither between the two patient groups nor 
between patients and controls. During vitamin E sup­
plementation, the maximum rate of oxidation and the 
maximum CD absorbance did not change in group A, 
but the maximum CD absorbance increased in group 
B ( P  =  0 .0 2 ) (Table 2 ) .
Concentrations of saturated and monounsaturated 
fatty acids in LD L, such as palmitic (C 1 6 ;0 ) ,  palmito- 
leic (C 1 6 :ln -7 ) ,  stearic ( C l 8 :0 ) ,  and oleic acid 
(C 1 8 ;ln -9 ) ,  were higher and those of linoleic acid 
(C18;2n~6) and docosahexaenic acid (C 22:6n -3) were 
lower in patients compared with controls; no differ­
ences were observed in a-linolenic (C 18:3n -3) and 
arachidonic acid content (C 2 0 :4 n -6 ) (Table 3 ) .  Dur­
ing the study period, arachidonic acid concentrations 
increased in group A and those of docosahexacnoic 
acid decreased in both groups, whereas palmitic acid 
concentrations decreased in group B (Table 3 ) .  There 
was a significant correlation between LD L linoleic ( but 
not arachidonic) acid and L D L  a-tocopherol concen­
trations ( r  =  0 .38, P =  0 .0 0 9 ) ,
In Table 4, the results of regression analyses for 
indexes of the LD L oxidizability and a-tocopherol and 
fatty acid content of L D L  are summarized. Lag times 
(Fig. 1) and the maximum CD absorbance (Fig. 3 )  
correlated positively with L D L  a-tocopherol concen­
trations, whereas the maximum rate of oxidation did 
not. Lag times were negatively, and both the maximum 
rate of oxidation and the maximum CD absorbance 
were positively related to L D L  linoleic and arachidonic 
acid concentrations (Fig. 4 ) .
DISCUSSION
This study documents that LD L resistance to oxida­
tion is impaired in vitamin E  deficient C F patients but 
can be normalized within 2 months of oral cv-tocoph- 
crol supplementation. Thus far, data on LD L resistance 
to oxidation comprised, with one exception/ '0 healthy 
subjects with a sufficient vitamin E  status before and 
after vitamin E supplementation or with varia­
tions in dietary fatty acid i n t a k e , b u t  not a larger 
cohort of vitamin E  deficient subjects and, in particular, 
not of CF patients. Whereas lag times correlated poorly 
with LD L «-tocopherol concentrations '^ ’0 in 
healthy subjects, the study patients, exhibiting a wide 
range of LD L «-tocopherol values, showed a signifi­
cant positive correlation. Interestingly, a few patients 
had unexpectedly long lag times despite a low LD L  
«-tocopherol content (Fig. I ) ,  an observation in 
agreement with that of Kleinveld et al/!n but lacking a 
final explanation.
During supplementation with 4 00  HJ/d of R R R -«-  
locopherol, plasma and LD L «-tocopherol concentra­
tions increased about threefold in the vitamin E defi­
cient, but not in the vitamin E  sufficient group, with 
plasma and LD L a-tocopherol concentrations higher 
than in healthy controls. This is in contrast to data 
suggesting that LD L a-tocopherol concentrations can 
be increased during vitamin E supplementation with­
out saturation in vitamin E  sufficient healthy sub­
je c ts1*121 ' 2} and perhaps indicates a plateau effect due 
to low LD L content of plasma in C F  patients, How­
ever, because a high proportion of patients in the vita­
min E sufficient group had already been on vitamin E 
supplements prior to study entry and the increase in 
the dosage was small compared to that in the vitamin 
E deficient group, final conclusions cannot be drawn 
for a ceiling effect from this study.
Lag times increased about twofold over baseline 
values in the vitamin E deficient, but not in the vitamin 
E sufficient group, reflecting the «-tocopherol increase 
in LD L and resulting in lag times that were even longer 
in vitamin E  sufficient patients compared with healthy 
controls.
The maximum rate of oxidation and CD absorbance 
did not differ between vitamin E deficient and suffi­
cient patients and healthy controls, and vitamin E sup­
plementation had no effect on these indexes. In con­
trast, healthy subjects showed significantly lower prop­
agation rates after vitamin E supplementation 
compared with baseline.21 CD absorbancc was posi­
tively related to the LD L «-tocopherol content only 
after vitamin E  supplementation in the present study, 
suggesting that a-tocophcrol does exert this particular
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protective action only at relatively high levels, as 
achieved after 2 months of supplementation. Recently, 
LDL of vitamin E deficient patients with fat malab­
sorption has been found less susceptible to oxidation
compared with controls.20 However, these patients also 
showed a low LD L content of linoleic acid, a major 
substrate for CD formation.
The fatty acid content of LD L had a major impact
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on the resistance to oxidation: Lag times were nega­
tively and rate of oxidation and CD absorbance were 
positively related to linoleic and arachidonic acid con­
centrations. This is in line with data from healthy sub­
jects focusing on LD L linoleic acid,20,2*1,25 It is not sur­
prising that linoleic acid plays a key role in LD L perox­
idation because it represents the major fatty acid in 
LD L, accounting for 35 to 50%  of fatty acids in healthy 
subjects24 and 29 ±  7%  in our patient population (com ­
pared to 5 ±  1% for arachidonic acid), and easily 
undergoes oxidation.^0 However, this study shows for 
the first time a significant effect of arachidonic acid 
content on the LD L resistance to oxidation.
C F patients have long been known to exhibit essen­
tial fatty acid deficiency 31; however, the mechanisms 
involved are not precisely known. In the present study, 
linoleic and docosahexaenoic acid concentrations in 
LD L were lower only in the vitamin E deficient but 
not in the vitamin E  sufficient group, compared with 
controls, and LD L linoleic (but not arachidonic acid) 
and a-tocopherol content were related to each other, 
indicating either a similarity in the underlying patho­
physiological mechanism of fat malabsorption with 
subsequent alterations in the vitamin E and fatty acid 
status or a direct protective effect of a-tocopherol on 
the loss of L D L  linoleic acid. The latter mechanism is 
further supported by an increase in arachidonic acid 
concentrations in the vitamin E  deficient group during 
supplementation. However, there was a decrease in 
docosahexaenoic acid during supplementation in both 
groups that does not support this mechanism.
The effect of LD L a~tocopherol concentrations on 
lag times, but not on the rate of oxidation and CD 
absorbance, and the influence of linoleic acid and ara­
chidonic acid content on the latter two indexes can at 
least in part be explained by the concept that, in the 
model of copper-induced L D L  oxidation, a-tocopherol 
and other endogenous antioxidants are consumed dur­
ing the lag phase and will therefore no longer be avail­
able for affecting the rate of oxidation or CD ab­
sorbance. The PU FA  content of LD L, particularly of 
linoleic and arachidonic acid, as the substrate for oxi­
dation will then become the major determinant of the 
LD L oxidizability.
In summary, this study documents that subclinical 
vitamin E  deficiency in C F patients exerts a significant 
effect on the LD L resistance to oxidation in vitro. Im­
paired L D L  resistance to oxidation of vitamin E  defi­
cient patients can be normalized within 2  months of 
4 00  IU /d  of RRR-a-tocopherol supplementation. We 
hypothesize that impaired resistance to oxidation of 
PUFAs is not confined to lipoproteins but might affect 
several tissues and, particularly, surfactant lipids in
the lung of C F patients. Hence, efficient vitamin E  
supplementation of CF patients is recommended as 
part of the therapeutic regime, However, dietary sup­
plementation with unsaturated fatty acids may increase 
the oxidizability of lipids and, consequently, increase 
the vitamin E  demands of C F  patients for an efficient 
protection of PUFAs against oxidation.
Acknowledgements'— Thu authors grate fully acknowledge the excel­
lent cooperation of the CF outpatient clinics o f  the University Hospi­
tal in Zurich, Switzerland (Professor H. Russi) ,  the Children's Hos­
pitals in Luzern ( Dr. J. Spalinger), Aarau ( Dr. P. Kilnzle), Chur ( Dr. 
D. Vtscher), vSt. Gullen (Dr. F. Sennhauser), and the Department of 
Internal Medicine, Kuntonsspital Winterthur (Dr. A. M uscl), all 
Switzerland, who allowed us to investigate their patients, as well us 
the determinations of plasma tocopherols and earotenoids in the 
Vitamin Research Department of Hoffmann-La Roche Ltd. (Basel, 
Switzerland) and plasma LD L cholesterol determinations in the In­
stitute of Clinical Chemistry and Hematology, St. Gallcn, Switzer­
land (Professor W. Riesen). W e thankTrudi Blau for expert techni­
cal assistance and Dorothea Stocssel, Irene Tanner, and Johanna 
Spuler for their assistance in the enrollment of patients and controls. 
This work was supported by grants from Swiss National Science 
Foundation, 32-33914* Austrian Science Foundation, MO 15 (Hahili- 
tationsstipeiulium of B. M, W. R.) and S07102-M B D  (Institute of 
Biochemistry, University of G raz), and Nestlé AC», Switzerland.
R E F E R E N C E S
1. Sokol, R. J.; Reardon, M. C.; Accurso, F. J.; Stall, C.; Narkew- 
icz, M.; Abman, S. 11.; Hammond, K. B. Fnt-soluble-vitamin 
status during the first year of life in infants with cystic fibrosis 
identified by screening of newborns. A m ../. Clin. Nutr. 50; 1 0 6 4 -  
1071; i m
2. Sitrin, M  D.; Lieberman, F.; Jensen, W. E.; Noronha, A.; Mil- 
hurn, C.; Addington, W. Vitamin H deficicncy and neurologic 
disease in cystic fibrosis. Ann. Int, Med. 107:51 *-54; 1987.
3. Ramsey, B. W.; Farrell, P. M.; Pencharz, P. B .;  The Consensus 
Committee. Nutritional support and management in cystic fi­
brosis. Am. J. Clin. Nutr. 5 5 :1 0 8 - 1 1 6 ;  1992.
4. Congden, P. J.; Brucc, G*; Rothburn, M. M.; Clarke, P. C. N,; 
Littlewood, J. M.; Kellchcr, J.; Losowsky, M. S. Vitamin status 
in treated patients with cystic fibrosis. Arch, Dis. Child. 5 6 :7 0 8 -
714; 1981.
5. Winklhofcr-Roob, B. M. Oxygen free radicals and antioxidants 
in cystic fibrosis: The concept o f  an oxidant-antioxidant imbal­
ance. Acta Paediatr. Sttppl. 3 9 5 :4 9 - 5 7 ;  1994.
6. James, D. R.; Alfaham, M.; Goodchild, M. C. Increased suscep­
tibility to peroxide-induced haemolysis with normal vitamin H 
concentrations in cystic fibrosis. Clin. Chim. Acta 2 0 4 :2 7 9 -2 9 0 ;
1991.
7. Brown, R. K.; Kelly, F. J. Evidence for increased oxidative 
damage in patients with cystic fibrosis. Pediatr. Res. 3 6 :4 8 7 -  
493; 1994.
8. Bilton, D.; Seabra, L.; Jones, M.; Webb, A. K.; Braganza, J. M. 
High breath pentane levels in patients with cystic fibrosis. Clin. 
Sci. 79  (Suppl.):20P (abstract); 1990.
9. Kneepkcns, C. M. F.; Ferreira, C.; Lepage, G.; Roy, C. C. Hy­
drocarbon breath test in cystic fibrosis: Evidence for increased 
lipid peroxidation, J, Pediatr. Gastroenterol. Nutr. 15:344 (ab­
stract); 1992.
10. Shwachman, H.; Mahmoodian, A. Pilocarpin iontophoresis 
sweat testing. Results o f  seven years’ experience. In: Rossi, E.; 
Stoll, E„ eds. Modern Problems in Pediatrics. Vol. 10, Part I. 
New York: Karger; 1 9 6 7 :1 5 8 -1 8 2 .
LDL resistance to oxidation in OF 733
11. Shwachman, I I . ; Kulc/.ycki, L. L. Long-term study of one hun­
dred five patients with cystic fibrosis. Am. J . Dis. Child, 9 6 : 6 -  
15; 1958.
12. Vuilleumier, J. P.; Keller, H. H.; Gysel, D.; Hun/.iker, F. Clinical 
chemical methods for the routine assessment of the vitamin 
status in human populations. Part I: The fat-soluble vitamins A 
and E, and /f-carotcne. Int. J . Vilam. Nittr. Res. 5 3 :2 6 5 -2 7 2 ;
1983.
13. Puhl, H.; Waeg, 0 , ;  Bsterbaucr, I I. Methods to determine oxida­
tion o f  low density lipoproteins. Merit, Enzvmol. 2 3 3 :4 2 5 -4 4 1 ;  
1994.
14. Waeg, G.; Puhl, P.; Esterbauer, U. LDL-oxidation— Results and 
relevance for atherogenesis and possible clinical consequences. 
hat. Sci. Techno!. 9 6 :2 0  22; 1994.
15. Dieber-Rotheneder. M.; Puhl, II.; Waeg, G.; Stricgl, G.; Es- 
terbauer, 11. Effect of oral supplementalion with D-cv-tocophcrol 
on the vitamin E content of human low density lipoproteins and 
resistance to oxidation. J. Lipid. Res. 3 2 :1 3 2 5 -1 3 3 2 ;  1991.
16. Kslerbauer, H.; Gcbicki, J.;  Puhl, 11.; Jttrgens, G. The role of 
lipid peroxidation and antioxidants in oxidative modification of 
LDL. Free Radic. Il'wi Med, 13:341 390; 1992.
17. Gieseg, S. P.; Esterbauer, 11. Low density lipoprotein is saturable 
by pro-oxidant copper. FEttS U$tt. 3 4 3 :1 8 8 -1 9 4 ;  1994.
18. Saltier, W.; Puhl, 11.; Ilayn, M.; Koslner, G. M.; Esterbauer, H. 
Determination of fatty acids in the main lipoprotein classes by 
capillary gas chromatography: B F (/methanol iransestcnfication 
o f  lyophiliml samples instead of Folch extraction gives higher 
yields. Anal. Hiociu 198:184 190; 1991.
19. I less, I).; Keller, 11, H.; Oberlin, B,; Bonfanti, R.; Schilep, W. 
Simultaneous determination of retinol, tocopherols, carotenes 
and lycopene in plasma by means of high-performance liquid 
chromatography on reversed phase, Int, J . Vitamin. Nutr, Res. 
6 1 :2 3 2  238; 1991.
20. Kleinvcld, H, A.; Naber, A. II. J.;  Slalenhoef, A. F. U.; De- 
mucker, P. N. M. Oxidation resistance, oxidation rate, and extent 
of oxidation of human low-densjty lipoprotein depend on the 
ratio o f  oleic acid content to linoleie acid content: studies in 
vitamin H deficient subjects. Free Radic. HioL Med. 15 :273— 
280; 1993.
21. Reaven, P, D.; Wit/.tum, J. L, Comparison of supplementation 
o f  RRR-«-tocopherol and racemie «-tocopherol in humans. E f­
fects on lipid levels and lipoprotein susceptibility to oxidation. 
Arterioscler. Thrtmh. 13 :6 0 1 ..608; 1993.
22. Princen, II. M. G.; Van Poppel, G.; Vogelezang, C.; Buytenhck, 
R.; Kok, F. J. Supplementation with vitamin B but not /^-caro­
tene in vivo protects low density lipoprotein from lipid peroxida­
tion in vitro. Effect o f  cigarette smoking. Arterioscler. Thmntb. 
12:554 562; 1992.
23.
24.
25.
26.
27.
28.
29.
30.
31.
Jialal, I.; Grundy, S. M. Effect o f  dietary supplementation with 
alpha-tocopherol on the oxidative modification o f  low density 
lipoprotein. J. Lipid Res. 3 3 : 8 9 9 - 9 0 6 ;  1992.
Reaven, P.; Parthasarathy, S.; Grasse, B ,  J . ;  Miller, E.; 
Steinberg, D.; Witztum, J. L. Effects o f  oleate-rich and linoleate- 
rich diets on the susceptibility of low density lipoprotein to 
oxidative modification in mildly hypercholesterolemia subjects. 
J. Clin. Invest. 9 1 :6 6 8 - 6 7 6 ;  1993.
Abbey, M.; Belling, G. B .;  Noakes, M .; Hirata, F.; Nestel, P. J. 
Oxidation o f  low-densily lipoproteins: Inlraindividual variability 
and the effect o f  dietary linoleate supplementation. Am. J, Clin. 
Nutr. 5 7 :3 9 1 - 3 9 8 ;  1993.
Jessup, W.; Rankin, S . M.; De Whalley, C. V .;  Moult, J .  R. S.; 
Scott, J.;  Leake, D. S . Alpha-tocopherol consumption during 
low density lipoprotein oxidation. Biochem. J. 2 6 5 :3 9 9 - 4 0 5 ;  
1990.
Babiy, A. V.; Gebicki, J. M.; Sullivan, D. R. Vitamin E  content 
and low density lipoprotein oxidizability induced by free radi­
cals. Atherosclerosis 8 1 : 1 7 5 - 1 8 2 ;  1990.
Klein veld, H. A.; Hak-Lemmcrs, H. L. M.; Stalenhoef, A, F. H.; 
Demacker, P. N. M. Improved measurement o f  low-density- 
lipoprotein susceptibility to copper-induced oxidation: Applica­
tion o f  a short procedure for isolating low-densily lipoprotein. 
Clin. Chem, 3 8 :2 0 6 6 - 2 0 7 2 ;  1992.
Bsterbaucr, H.; Diebcr-Rothcnedcr, M,; Stricgl, G.; Waeg, G. 
Role o f  vitamin E in preventing the oxidation o f  low-density 
lipoprotein. Am. J. Clin. Nntr. 5 3 : 3 1 4 S - 3 2 1 S ;  1991. 
Esterbauer, H.; JUrgens, G,; Quehenberger, O,; Koller, E, Autox- 
idation of human low density lipoprotein: Loss o f  polyunsatu­
rated fatty acids and vitamin E  and generation o f  aldehydes. J, 
Lipid Res. 2 8 : 4 9 5 - 5 0 9 ;  1987.
Roscnlund, M. L.; Kim, H. K.; Krilchcvsky, D. Essential fatty 
acids in cystic fibrosis. Nature 2 5 1 :7 1 9 ;  1974.
ABBREVIATIONS
CD— conjugated dienes 
C F — cystic fibrosis
ED TA — ethylenediamine tctraacetic acid 
GC— gas chromatography
H PLC— high-performance liquid chromatography
L D L — low density lipoprotein
M DA— malondialdehyde
P B S — phosphate-buffered saline
PU FA s— polyunsaturated fatty acids
